dr. shapiro on the results of the ibis ii trial
Published 10 years ago • 98 plays • Length 1:49Download video MP4
Download video MP3
Similar videos
-
3:15
the ibis-ii breast cancer prevention trial - professor jack cuzick
-
0:53
final results of the phase 3 data trial assessing aromatase inhibition in hr breast cancer
-
0:18
copy of dr. esserman on the elements of the i-spy 2 trial in breast cancer
-
1:24
the ibis-i breast cancer clinical trial - breast cancer trials
-
7:15
how long do aromatase inhibitor side effects last? all you need to know
-
4:44
is anastrozole the new wonder drug? - with dr tasha
-
16:15
tamoxifen & aromatase inhibitors: how to tolerate them for best results!
-
3:39
comparable outcomes, different toxicities with anastrozole, tamoxifen in dcis | ivana sestak
-
1:22
dr. pusztai on rationale for the i-spy 2 trial with durvalumab/olaparib combo in her2- breast cancer
-
7:26
s1222 hr , stage iv breast cancer: fulvestrant w/wo everolimus /- anastrozole
-
2:15
i-spy2.2: emerging biomarkers in breast cancer
-
7:26
i-spy 2: immunotherapy biomarkers in early breast cancer
-
6:02
sabcs 2013: anastrozole cuts breast cancer cases by more than 50% in high risk women
-
0:55
dr pusztai on molecular residual disease monitoring in early breast cancer
-
1:04
dr. brufsky on the disease-free survival of aromatase inhibitors for breast cancer
-
1:20
dr. cella on the side effect focus of the axitinib and sorafenib trial
-
1:20
dr. tripathy on 10 versus 5 years of aromatase inhibitors
-
4:54
side effects of aromatase inhibitors, from a medical oncologist's view
-
0:45
dr. brose describes the decision trial
-
4:39
anastrozole duration for post-menopausal breast cancer patients after 5 years of endocrine therapy
-
0:20
cutting the risk of breast cancer
-
37:53
addressing the challenge of endocrine-resistant breast cancer